Formulation Development
uniQure to Acquire Corlieve Therapeutics & Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
uniQure N.V. recently announced it has entered into a definitive agreement to acquire Corlieve Therapeutics and its lead program, which will be known as….
vTv Therapeutics & Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development & Commercialization of Cancer Treatment
vTv Therapeutics Inc. and Cantex Pharmaceuticals, Inc. recently announced they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to….
Vectura Signs Preclinical Development Agreement With Incannex
Vectura Group plc recently announced it has signed an agreement with Incannex Healthcare Limited, an Australian cannabinoid medicines development company, to provide preclinical development services for….
Syneos Health Accelerates Decentralized Clinical Trial Delivery, Unveils New Collaboration With Site Sponsors
Syneos Health recently expanded its Decentralized Clinical Trial capabilities to include a dedicated Decentralized Clinical Trials Site Advocacy Group, continuing the momentum for….
Processa Pharmaceuticals Enters Licensing & Development Agreement With Ocuphire Pharma
Processa Pharmaceuticals, Inc. recently announced it has entered into a licensing agreement with Ocuphire Pharma, Inc. to license in RX-3117. RX-3117 is an oral, anticancer…
Onconova Therapeutics Announces Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined With Immune Checkpoint Blockade
Onconova Therapeutics, Inc. recently announced the publication of a preclinical study in the journal Molecular Cancer. The study, titled Novel Induction of CD40 Expression by…
BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-Based BNT111 in Patients With Advanced Melanoma
BioNTech SE recently announced the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899). The study is evaluating the…
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
Biogen Inc. recently announced the first patient has been dosed in the global clinical study, TOPAZ-1. The Phase 3 study will evaluate the clinical efficacy…
Evonik & Stanford University Sign Research Collaboration: Evonik to Market & Develop New Drug Delivery Platform for mRNA & Gene Therapy
Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs)…..
Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement With Gilead Sciences
Jounce Therapeutics, Inc. recently announced the US FDA clearance of its Investigational New Drug (IND) application for JTX-1811, an anti-CCR8 antibody, for which Gilead Sciences, Inc. has exclusive rights….
iTeos Therapeutics & GSK Announce Development & Commercialization Collaboration
iTeos Therapeutics and GlaxoSmithKline plc recently announced an agreement to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody currently in Phase 1 development as a….
VERAXA Biotech & Quadira Biosciences Enter Partnership on ADC Development
VERAXA Biotech GmbH recently announced it has entered into a partnership agreement with Quadira Biosciences AG, Zug, Switzerland, to jointly develop a suite of novel ADCs for the….
LexaGene Detects a Slow-Growing Bacterium at Least 36-Times Faster Than Conventional Methods With Potential to Increase Vaccine Safety & Supply
LexaGene Holdings, Inc. recently announced it has successfully utilized the MiQLab System to detect the presence of a slow growing bacterium, responsible for millions of dollars…
Enterprise Therapeutics Doses First Subjects in Phase 1 Trial for Novel Cystic Fibrosis Therapy
Enterprise Therapeutics Ltd recently announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis (CF) therapy,…
Inceptor Bio Launches Next-Generation CAR-T, CAR-M, & NK/NKT Platform Focused on Advancing Cell & Gene Therapies to Cure Difficult-to-Treat Cancers
Inceptor Bio recently announced it is developing multiple next-generation cell and gene therapy platforms to cure difficult-to-treat cancers. Inceptor Bio will create a portfolio of…
HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator
HiberCell recently announced the initiation of a Phase 1a multicenter, open-label, dose escalation trial of its orally administered HC-5404-FU in patients with selected metastatic solid…
Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line & Beyond HNSCC
Cue Biopharma, Inc. recently announced it has dosed the first patient in the Part B expansion phase of its Phase 1 monotherapy clinical trial of…
Cocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 & Two Prominent SARS-CoV-2 Variants
Cocrystal Pharma, Inc. recently announced its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active against SARS-CoV-2 and two prominent SARS-CoV-2 variants. A third-party laboratory…
Liminatus Pharma R&D Consortium Companion Diagnostic YN 1203 Demonstrates ~70% Sensitivity & Specificity in Clinical Testing
Liminatus Pharma recently announced its companion diagnostic to support checkpoint inhibitor therapies, YN1203 CDx liquid biopsy test (YN1203 ELISA Kit), has demonstrated….
Cyclerion Therapeutics Announces Global Licensing Agreement With Akebia Therapeutics
Cyclerion Therapeutics, Inc. recently announced it has entered into an exclusive, global license agreement with Akebia Therapeutics, Inc., a leading biopharmaceutical company focused on kidney disease, for the….
